GlassScriptPhysician profile
Aaron Taylor Clark
NPI 1134439581
$5,858.18
in general payments reported to CMS, 2019-2025
60 companies · $562 in 2025
The $562 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $955 · 2021: $1,292 · 2022: $923 · 2023: $633 · 2024: $417 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,149.21 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Astrazeneca Pharmaceuticals LP | $579.67 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $423.65 | 2020-2024 | Vraylar |
| Novo Nordisk INC | $358.33 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $280.77 | 2019-2025 | Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $205.34 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $188.29 | 2019-2020 | |
| Amarin Pharma, INC. | $172.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $155.27 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $134.65 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $127.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.35 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $112.81 | 2019-2023 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $103.50 | 2022 | |
| Amgen INC. | $103.18 | 2020-2023 | Repatha, Otezla |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.